BUHLMANN Citations Archives - Page 2 of 14

100 BÜHLMANN Calprotectin Publications

BÜHLMANN launched its first fecal calprotectin assay over 10 years ago and since then has developed into THE CALPROTECTIN COMPANY with the highest quality standards. The offerings include the FDA 510(k) cleared BÜHLMANN fCAL® ELISA, the FDA 510(k) cleared automated BÜHLMANN fCAL® turbo (in combination with CALEX® Cap fecal extraction device) for testing on most

Therapeutic Drug Monitoring in Crohn’s Disease Patients

Bodini, G. et al. Therapeutic Drug Monitoring in Crohn's Disease Patients, A Comparison Between Homogenous Mobility Shift Assay and Point of Care Method. UEGW 2019, Feb 09 – 11, 2018. Barcelona, Spain. P1750. Read Citation BÜHLMANN Quantum Blue® Infliximab is for Research Use Only in the US. Not for use in diagnostic procedures in the US. Health

Clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc

IBDoc® Citation: ECCO 2019 Poster Walmsley et al. Poster: P630 A non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. ECCO 2019: Inflammatory Bowel Diseases 14th Congress, March 6-9, 2019, Copenhagen/Denmark. Highlights from this Poster “Use of IBDsmart and IBDoc® in

Use of Fecal Calprotectin Home Testing in Patients with Inflammatory Bowel Disease

BÜHLMANN IBDoc®: Orfanourdaki et al. The Real World Use of Fecal Calprotectin Home Testing in Patients with Inflammatory Bowel Disease Under Maintenance Treatment with Adalimumab. UEGW 2019, Feb 09 – 11, 2018. Barcelona, Spain. P1074 Read Citation Health Canada Licence: 98903, Device class: 3 BÜHLMANN IBDoc® is Not Available for Sale in the US.

Clinical Accuracy of the BÜHLMANN fCAL® ELISA in the Differentiation of IBD from IBS

BÜHLMANN fCAL® ELISA Citation Berinstein, J. et al. The Clinical Accuracy of the BÜHLMANN fCAL® ELISA in the Differentiation of Inflammatory Bowel Disease from Irritable Bowel Syndrome: A Multi-Center Prospective Case-Control Study. Crohn's & Colitis 360 (2019). DOI: https://doi.org/10.1093/crocol/otz037. [Accepted Manuscript] Highlight from this Publication “The BÜHLMANN fCAL ELISA demonstrates excellent discriminating between IBD and IBS.”

Usability of IBDoc- Novel Fecal Calprotectin Home-Based Rapid Test

IBDoc® Citation: Røer MJ., 2019, Usability of IBDoc, a Novel Fecal Calprotectin Home-Based Rapid Test in Clinical Practice, Point of Care: September 2019 - Volume 18 - Issue 3 - p 85–91. doi: 10.1097/POC.0000000000000192 Highlights from this Publication “Clearly, the majority of the IBD patients found the home-based test valuable...” Read Citation Health Canada License: 98903

The Way to Total Automation of Calprotectin Measurement in Faeces with BUHLMANN fCAL® turbo

BÜHLMANN fCAL® turbo: Schallberger, Y. et al. The Way to Total Automation of Calprotectin Measurement in Faeces with BUHLMANN fCAL® turbo. Swiss MedLab 2016, 13. – 16. June 2016. Berne, Switzerland. Poster Highlights from this Publication “ ...Combined with the CALEX® Cap extraction device the fecal calprotectin testing workflow is further simplified thus reducing hands-on-time by 70%. " Read Citation

Head-to-head comparison of three stool calprotectin tests for home use

IBDoc® Citation: Haisma et al. Head-to-head comparison of three stool calprotectin tests for home use. Plos ONE. https://doi.org/10.1371/journal.pone.0214751 April 18, 2019 Highlights from this Publication “ …We observed that 119 of 125 IBDoc readings ≥ 500 μg/g were concordant with fCAL results (95%), compared to 35% and 49% for the QuantOnCal—IDK-Calprotectin and CalproSmart—Calprotectin-ALP pairs.…” “The CalproSmart

Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients

BÜHLMANN fCAL® ELISA Citation Foster, A. et al. Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn's disease patients. World J Gastroenterol. PMID: 30886509 DOI: 10.3748/wjg.v25.i10.1266. Highlight from this Publication ..."Notably, in keeping with adult IBD practice, our study shows that children should also have FC levels checked every 3 mo to ensure adequate monitoring."… Read Citation BÜHLMANN

Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring

IBDoc® Citation: Wei, S. , Tung, C. et al. Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring. Intestinal Research 2018;16(4):546-553. DOI: https://doi.org/10.5217/ir.2018.00052 PMID: 30301339 Highlights from this Publication “96% of the patients were satisfied with the home test..." “71% of patients preferred the home test method monitor

Category: BUHLMANN Citations

100 BÜHLMANN Calprotectin Publications

Therapeutic Drug Monitoring in Crohn’s Disease Patients

Clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc

Use of Fecal Calprotectin Home Testing in Patients with Inflammatory Bowel Disease

Clinical Accuracy of the BÜHLMANN fCAL® ELISA in the Differentiation of IBD from IBS

Usability of IBDoc- Novel Fecal Calprotectin Home-Based Rapid Test

The Way to Total Automation of Calprotectin Measurement in Faeces with BUHLMANN fCAL® turbo

Head-to-head comparison of three stool calprotectin tests for home use

Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients

Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring

ABOUT US

SOCIAL MEDIA

QUICK LINKS

CONTACT US